Precision Biosciences Total Assets Growth & History (DTIL)
Precision Biosciences's total assets was $154.4M for fiscal 2025.
View full Precision Biosciences company overviewPrecision Biosciences annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $154.4M | $18.0M | +13.22% |
| 2024 | 2024-12-31 | $136.4M | −$23.4M | −14.64% |
| 2023 | 2023-12-31 | $159.8M | −$78.4M | −32.91% |
| 2022 | 2022-12-31 | $238.2M | $26.7M | +12.61% |
| 2021 | 2021-12-31 | $211.5M | $61.3M | +40.85% |
| 2020 | 2020-12-31 | $150.2M | −$85.1M | −36.17% |
| 2019 | 2019-12-31 | $235.2M | $96.6M | +69.72% |
| 2018 | 2018-12-31 | $138.6M | — | — |
Precision Biosciences quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $125.9M | $17.0M | +15.60% |
| Q1 2026 | 2026-03-31 | $143.9M | $19.5M | +15.66% |
| Q4 2025 | 2025-12-31 | $154.4M | $18.0M | +13.22% |
| Q3 2025 | 2025-09-30 | $93.5M | −$59.7M | −38.99% |
| Q2 2025 | 2025-06-30 | $108.9M | −$56.9M | −34.30% |
| Q1 2025 | 2025-03-31 | $124.4M | −$60.3M | −32.66% |
| Q4 2024 | 2024-12-31 | $136.4M | −$23.4M | −14.64% |
| Q3 2024 | 2024-09-30 | $153.3M | −$11.1M | −6.75% |
| Q2 2024 | 2024-06-30 | $165.8M | −$15.9M | −8.75% |
| Q1 2024 | 2024-03-31 | $184.7M | −$19.8M | −9.66% |
| Q4 2023 | 2023-12-31 | $159.8M | −$78.4M | −32.91% |
| Q3 2023 | 2023-09-30 | $164.3M | −$107.4M | −39.52% |
| Q2 2023 | 2023-06-30 | $181.7M | −$115.5M | −38.86% |
| Q1 2023 | 2023-03-31 | $204.5M | $23.2M | +12.77% |
| Q4 2022 | 2022-12-31 | $238.2M | $26.7M | +12.61% |
| Q3 2022 | 2022-09-30 | $271.7M | $44.5M | +19.60% |
| Q2 2022 | 2022-06-30 | $297.2M | $67.0M | +29.14% |
| Q1 2022 | 2022-03-31 | $181.4M | −$81.0M | −30.87% |
| Q4 2021 | 2021-12-31 | $211.5M | $61.3M | +40.85% |
| Q3 2021 | 2021-09-30 | $227.2M | $58.5M | +34.69% |
| Q2 2021 | 2021-06-30 | $230.1M | $45.9M | +24.93% |
| Q1 2021 | 2021-03-31 | $262.3M | $48.1M | +22.46% |
| Q4 2020 | 2020-12-31 | $150.2M | −$85.1M | −36.17% |
| Q3 2020 | 2020-09-30 | $168.7M | −$91.6M | −35.19% |
| Q2 2020 | 2020-06-30 | $184.2M | −$87.7M | −32.26% |
| Q1 2020 | 2020-03-31 | $214.2M | $47.4M | +28.42% |
| Q4 2019 | 2019-12-31 | $235.2M | $96.6M | +69.72% |
| Q3 2019 | 2019-09-30 | $260.3M | — | — |
| Q2 2019 | 2019-06-30 | $271.9M | — | — |
| Q1 2019 | 2019-03-31 | $166.8M | — | — |
| Q4 2018 | 2018-12-31 | $138.6M | — | — |
Precision Biosciences total assets trends
Over the last five fiscal years, Precision Biosciences's total assets increased from $150.2M to $154.4M, a change of $4.3M. The latest reported quarter, Q2 2026, shows $125.9M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Precision Biosciences source filings ↗